Literature DB >> 6195266

Fate and mechanism of clearance of PSAP, a schistosome antigen, in schistosomiasis.

T Nash.   

Abstract

The clearance and the factors modulating clearance of PSAP, a glycoprotein excretory-secretory antigen of Schistosoma mansoni, were determined in control and infected mice. After i.v. injection, PSAP was removed rapidly from the circulation of both infected and control mice. The half-life in control mice was about 2.5 min compared to 60 min for the proteoglycan schistosome gut antigen, GASP. Injection of PSAP-containing immune complexes into control mice or of PSAP into infected mice resulted in a prolongation of clearance. In infected mice, the delay in clearance correlated with the amount of anti-PSAP. Marked inhibition of clearance was induced by coinjection of asialofetuin with PSAP, indicating a galactose-mediated clearance mechanism. Furthermore, the clearance of model complexes was delayed to a greater degree after co-injection of asialofetuin than with aggregated gamma-globulin, suggesting that complexes were primarily removed by the galactose receptor. The delay in clearance of antigens may result in immune complex deposition in abnormal locations.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6195266

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Detection and quantification of circulating antigen in schistosomiasis by a monoclonal antibody. I. Specificity analysis of a monoclonal antibody with immunodiagnostic capacity.

Authors:  J A Nogueira-Queiroz; C Lutsch; M Capron; J P Dessaint; A Capron
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

Review 2.  Immunopathology of Schistosoma mansoni infection.

Authors:  D L Boros
Journal:  Clin Microbiol Rev       Date:  1989-07       Impact factor: 26.132

3.  Predominance of IgA deposits in glomeruli of Schistosoma mansoni infected mice.

Authors:  A K el-Sherif; D Befus
Journal:  Clin Exp Immunol       Date:  1988-01       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.